IPO Profile

Phase Forward
880 Winter Street, Waltham, Massachusetts 02451
Tel: 888-703-1122
Web: www.phaseforward.com
Ticker: PFWD
Stock Exchange: Nasdaq
Shares Issued: 5,250,000.00
Price Offered: $7.50
Amount Raised: $39,375,000.00

Underwriters:
Thomas Weisel Partners LLC
Piper Jaffray
Raymond James



Company Description:
Phase Forward is a leading provider of integrated enterprise-level software products, services and hosted solutions for use in the mission-critical clinical trial component of our customers� global research and development initiatives. Our customers include pharmaceutical, biotechnology and medical device companies, as well as academic institutions, clinical research organizations and other entities engaged in clinical trials. By automating essential elements of the clinical trial process, we believe our products allow our customers to accelerate the market introduction of new medical therapies and corresponding revenue, reduce overall research and development expenditures, enhance existing data quality control efforts and reduce clinical and economic risk. We believe our enterprise software and hosted solutions are the most widely-adopted commercial electronic data capture, data management and adverse event reporting solutions in the clinical trial marketplace, having been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants and 300 therapeutic compounds and medical devices. Our customer base includes over 220 companies, such as AstraZeneca Pharmaceuticals LP, Corixa Corporation, Guidant Corporation, Eli Lilly and Company, Mayo Clinic College of Medicine, Novartis AG and Schering-Plough Research Institute.